The safety and anti-tumor eŠect of oncolytic virus have been reported in a clinical study conducted in Japan. We have engineered a novel multimutated tumor-speciˆc oncolytic herpes virus, harboring a smooth muscle-speciˆc calponin promoter. Since tumor cells present in a hypoxic environment are known to be resistant to chemotherapy and radiotherapy, we also engineered a novel oncolytic herpes virus targeting a speciˆc tumor microenvironment, which harbors a gene encoding a fusion protein of oxygen-dependent degradation (ODD) domain of HIF1a and ICP4, a master viral transcription factor required for replication. The recombinant virus selectively replicates in and disrupts the target tumor cells, including human sarcoma and malignant mesothelioma cells which are unresponsive to chemotherapy and molecular targeted therapy. We conˆrmed signiˆcant anti-tumor eŠects of the novel viruses in vivo in an allogeneic experimental model of an undiŠerentiated pleomorphic sarcoma (malignantˆbrous histiocytoma; MFH) spontaneously generated in immunocompetent Fischer rats. Our viruses, manufactured in the Master Virus Seed Stock in the Good Manufacturing Practice facility will become novel agents that enable tumor cells unresponsive to conventional treatment to be disrupted. 
Clinical phase I/II trails of oncolytic HSV-1 targeting glioma (G207, HSV1716, G47D), metastatic colon cancer in liver (NV1020) and metastatic breast cancer in skin (OncoVEXGM-CSF, HF10) were carried out in the U.S., England and Japan. These HSV-1 mutants were deˆcient for ribonucleotide reductase (RR) essential for the viral replication or deˆcient for g34.5 relevant to the viral neurotoxicity(G207 is a mutant deˆcient for RR and HSV1716 and OncoVEXGM-CSF are mutants deˆcient for g34.5. HF10 is a natural mutant deˆcient for UL56 relevant to neurotoxicity. 
Fig. 3b. Expression of Calponin 1 in Mesothelioma Cells
Immunohistochemistry demonstrating calponin 1, a marker for smooth muscle cells, is also expressed in sarcoma and mesothelioma but not in adenocarcinoma. We developed targeted oncolytic HSV-1 replicating and destructing selectively in calponin 1-expressing tumors by controlling the expression of ICP4 which is essential for initiating viral replication with calponin promoter. Expression of glucose transporter (Glut1) (left) and HIF1a (right). Mesothelioma cells in the hypoxic region show resistance to pharmacologic therapies such as chemotherapy and molecular targeted therapy as well as radiotherapy. It has been reported that oncolytic HSV-1 replicates preferentially in the hypoxic environment. 20) We constructed a fusion protein between amino terminal region of ICP4, a transcription factor essential for viral replication, and a 56 amino-acid sequence regulating oxygen-dependent protein degradation of HIF1a. In this oncolytic HSV-1, ICP4 protein is degraded in the normoxic condition and is expressed in the hypoxic condition. Thus, the oncolytic HSV-1 selectively replicates in tumor cells in the hypoxic condition and destructs them. 
